Lumos Diagnostics (ASX: LDX) Share Price and News

Ms Le Grice has over two decades of executive experience spanning health technology commercialization, venture capital, capital raising and industry advocacy. Formerly an Investment Director at healthcare VC firm, BioScience Managers, Ms. Le Grice has experience across buy side and sell side transactions specifically within the health and medical technology sectors. As Founder and CEO of ANDHealth since 2017, Ms. Le Grice has created a digital health commercialization organization. She is the Chair of the Disclosure Committee and a Member of the Risk Committee.

Ms Robson has more than 25 years of experience in management, finance and investment. Ms. Robson currently chairs the Board of fully owned subsidiary Equity Trustees Superannuation Limited. Ms. Robson's other Board appointments include serving as a Non-Executive Director for an Australia customer owned bank, Newcastle Greater Mutual Group, where she chairs the Audit Committee. She is Chair of the Risk Committee.

Mr Mehren served as President and Chief Executive Officer as well as a Director of Accelerate Diagnostics from 2012 to 2020. During his tenure, the company developed and launched its groundbreaking Accelerate Pheno instrument. Prior to this, Mr. Mehren was the Head of Global Business for Ventana Medical Systems and Roche Tissue Diagnostics managing its four business units. He also held various global leadership positions with Ventana including Senior Vice President of Emerging Businesses and Chief Financial Officer. Mr Mehren was also Managing Director, Partner and Head of P&M Corporate Finance's life sciences practice.

Mr Lanyon has more than 25 years of experience in strategy, sales and operations with a demonstrated record in the global commercialization of technology infused healthcare products. Mr. Lanyon currently serves as Executive Director and co-founder of Planet Innovation and as a Non-Executive Director of Paragon Funds Management. Previously, Mr. Lanyon held international executive roles with Leica Microsystems, part of Danaher Corporation, and ASX listed Vision Systems Ltd where he was responsible for establishing Vision Biosystem's sales, marketing, and service operations throughout the EU, Middle East, Latin America, and Asia Pacific. He is a Member of the Disclosure Committee, Member of the Risk Committee.

Mr Ward has more than 30 years of biotech and medical technology experience at global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic. During his career, Mr. Ward held executive positions where he developed and implemented novel business strategies and introduced products to the practice of medicine. Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for women's healthcare to improve clinical results. Mr. Ward also served as the CEO of Personal Genome Diagnostics (PGDx) where he led the organization's change from a clinical laboratory testing service into a functional molecular invitro diagnostics (IVD) company. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.

-

-

-

-

-

-

-

-

-

-

-